Ocugen (OCGN) Operating Leases (2019 - 2026)
Ocugen's (OCGN) quarterly Operating Leases came in at $4.1 million in Q1 2026, up 20.01% YoY from $3.4 million in Q1 2025, and up 17.4% on a QoQ basis from $3.5 million in Q4 2025.
Analysis
Ocugen (OCGN) Operating Leases (2019 - 2026) Analysis & Trends
Ocugen (OCGN) has 8 years of Operating Leases data on file, last reported at $4.1 million in Q1 2026.
- Quarterly Operating Leases rose 20.01% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (up 20.01% YoY) and the FY2025 annual result came in at $3.5 million, down 8.82% from the prior year.
- Operating Leases advanced to $4.1 million in Q1 2026, from $3.5 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $4.8 million in Q2 2025 to a low of $1.2 million in Q1 2022.
- A 5-year average of $3.6 million and a median of $3.8 million in 2022 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases surged 231.84% — and 2023, when it declined 15.94%.
- Tracing OCGN's Operating Leases over 5 years: stood at $4.1 million in 2022, then decreased by 12.68% to $3.6 million in 2023, then rose by 7.43% to $3.8 million in 2024, then slipped by 8.82% to $3.5 million in 2025, then increased by 17.4% to $4.1 million in 2026.
- The last three Operating Leases figures came in at $4.1 million (Q1 2026), $3.5 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.88 Mn |
| Mar 31, 2026 | 4.10 Mn |
| Dec 31, 2025 | 3.49 Mn |
| Sep 30, 2025 | 4.56 Mn |
| Jun 30, 2025 | 4.80 Mn |
| Mar 31, 2025 | 4.15 Mn |
| Dec 31, 2024 | 3.83 Mn |
| Sep 30, 2024 | 3.90 Mn |
| Jun 30, 2024 | 4.01 Mn |
| Mar 31, 2024 | 4.00 Mn |
| Dec 31, 2023 | 4.14 Mn |
| Sep 30, 2023 | 3.16 Mn |
| Jun 30, 2023 | 3.31 Mn |
| Mar 31, 2023 | 3.45 Mn |
| Dec 31, 2022 | 4.09 Mn |
| Sep 30, 2022 | 3.76 Mn |
| Jun 30, 2022 | 3.89 Mn |
| Mar 31, 2022 | 1.18 Mn |
| Dec 31, 2021 | 1.59 Mn |
| Sep 30, 2021 | 1.45 Mn |